FDA-approved antiplatelet drug shows potential as new, low-cost heart failure therapy

By | August 24, 2021
Sarpogrelate, an antiplatelet medication, has potential as a new heart failure therapy and, according to researchers, could potentially decrease health care costs associated with cardiovascular disease, according to preliminary animal research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions 2021.